For years, PCOS was often diagnosed through the most visible disruptions: irregular periods, acne, facial hair, weight gain, or difficulty conceiving. That made many patients enter the healthcare system through gynecology, usually when menstrual, reproductive, or visible hormonal symptoms became hard to ignore.The shift from Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome encourages clinicians to look earlier, wider, and more systematically at the condition. A Wider Starting Point The old name placed the ovary at the center of the condition. PMOS keeps ovarian function in the picture, but it widens the diagnostic lens to include the hormone and metabolic systems that are often involved from the start. This distinction matters because the condition is not defined by harmful ovarian cysts. In fact, ovarian cysts are not required for diagnosis, and some women with PCOS may not show polycystic ovaries on ultrasound at all. The newer name, therefore, helps move diagnosis beyond a scan-based or ovary-only understanding, and closer to how the condition actually presents and manifests itself in the body. From Period Problem To Whole-body Assessment With PMOS, diagnosis should become less dependent on ultrasound and more attentive to the full clinical pattern. Doctors will still look at irregular or absent periods and signs of high androgen levels, such as acne, excess facial or body hair, hair thinning, and raised testosterone levels, where tested. But the newer framing should also make metabolic screening routine, especially for insulin resistance, type 2 diabetes risk, blood pressure, cholesterol, obesity, sleep apnea, and fatty liver-related concerns. WHO describes PCOS as a chronic metabolic condition that can persist beyond the reproductive years, with symptoms and risks varying from person to person. PMOS: Why This Change Could Reduce Missed Diagnosis The scale of underdiagnosis is large. It is estimated that PCOS affects 10–13% of reproductive-aged women, while up to 70% of affected women worldwide may not know they have the condition. A name that leads with “polyendocrine” and “metabolic” may help clinicians connect symptoms that were previously treated separately: a dermatologist sees acne, a gynecologist sees irregular periods, an endocrinologist sees insulin resistance, and a mental-health professional sees anxiety or poor quality of life. What Needs To Change Now The diagnosis is not changing into a different disease. The condition remains the same, but the way it is understood may become broader and more accurate. The real opportunity lies in better recognition: fewer patients being told their symptoms are only about cysts, weight, periods or fertility, and more patients being assessed for the long-term hormonal and metabolic risks that can come with the condition. For this shift to matter, awareness must grow across the medical fraternity and among patients, so PMOS is approached as a multi-system condition; symptoms are recognized earlier, and care becomes more connected from the beginning.(Written by Dr. Rashmi Dharaskar, Sr. Consultant Obstetrics and Gynaecologist at Surya Mother & Child Super Specialty Hospital).